OBJECTIVE: To investigate the efficacy and tolerability of analgesic and adjuvant pain drugs typically administered in primary care for the management of patients with sciatica. DESIGN: Systematic review. Data source International Pharmaceutical Abstracts, PsycINFO, Medline, Embase, Cochrane Central Register of Clinical Trials (CENTRAL), CINAHL, and LILACS. STUDY SELECTION: Randomised controlled trials assessing the efficacy and tolerability of drugs versus placebo or other treatment for sciatica. DATA EXTRACTION: Two independent reviewers extracted data and assessed methodological quality using the PEDro scale. Pain and disability outcomes were converted to a common 0 to 100 scale. Data were pooled with a random effects model, and the GRADE approach was used in summary conclusions. RESULTS: Twenty three published reports met the inclusion criteria. The evidence to judge the efficacy of non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, antidepressants, anticonvulsants, muscle relaxants, and opioid analgesics ranged from moderate to low quality. Most of the pooled estimates did not favour the active treatment over placebo. The pooled results of two trials of corticosteroids (mean difference in overall and leg pain -12.2, 95% confidence interval -20.9 to -3.4) and a single trial of the anticonvulsant gabapentin for chronic sciatica (mean difference in overall pain relief -26.6, -38.3 to -14.9) showed some benefits but only in the short term. The median rate of adverse events was 17% (interquartile range 10-30%) for the active drugs and 11% (3-23%) for placebo. Trial limitations included failure to use validated outcome measures, lack of long term follow-up, and small sample size. CONCLUSIONS: As the existing evidence from clinical trials is of low quality, the efficacy and tolerability of drugs commonly prescribed for the management of sciatica in primary care is unclear.
AD - George Institute for Global Health, University of Sydney, PO Box M201, Camperdown, Sydney, NSW 2050, Australia. rafaelzambelli@gmail.com AN - 22331277 BT - BMJ (Clinical Research Ed.) ET - 2012/02/15 LA - eng N1 - Pinto, Rafael ZambelliMaher, Chris GFerreira, Manuela LFerreira, Paulo HHancock, MarkOliveira, Vinicius CMcLachlan, Andrew JKoes, BartMeta-AnalysisResearch Support, Non-U.S. Gov'tReviewEnglandBMJ (Clinical research ed.)BMJ. 2012 Feb 13;344:e497. doi: 10.1136/bmj.e497. N2 -OBJECTIVE: To investigate the efficacy and tolerability of analgesic and adjuvant pain drugs typically administered in primary care for the management of patients with sciatica. DESIGN: Systematic review. Data source International Pharmaceutical Abstracts, PsycINFO, Medline, Embase, Cochrane Central Register of Clinical Trials (CENTRAL), CINAHL, and LILACS. STUDY SELECTION: Randomised controlled trials assessing the efficacy and tolerability of drugs versus placebo or other treatment for sciatica. DATA EXTRACTION: Two independent reviewers extracted data and assessed methodological quality using the PEDro scale. Pain and disability outcomes were converted to a common 0 to 100 scale. Data were pooled with a random effects model, and the GRADE approach was used in summary conclusions. RESULTS: Twenty three published reports met the inclusion criteria. The evidence to judge the efficacy of non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, antidepressants, anticonvulsants, muscle relaxants, and opioid analgesics ranged from moderate to low quality. Most of the pooled estimates did not favour the active treatment over placebo. The pooled results of two trials of corticosteroids (mean difference in overall and leg pain -12.2, 95% confidence interval -20.9 to -3.4) and a single trial of the anticonvulsant gabapentin for chronic sciatica (mean difference in overall pain relief -26.6, -38.3 to -14.9) showed some benefits but only in the short term. The median rate of adverse events was 17% (interquartile range 10-30%) for the active drugs and 11% (3-23%) for placebo. Trial limitations included failure to use validated outcome measures, lack of long term follow-up, and small sample size. CONCLUSIONS: As the existing evidence from clinical trials is of low quality, the efficacy and tolerability of drugs commonly prescribed for the management of sciatica in primary care is unclear.
PY - 2012 SN - 1756-1833 (Electronic)0959-535X (Linking) EP - e497 T2 - BMJ (Clinical Research Ed.) TI - Drugs for relief of pain in patients with sciatica: systematic review and meta-analysis VL - 344 ER -